

# The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

NCT07057414

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.
Enrollment	11 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Study participants must meet all of the following criteria to be enrolled in this trial:
- Voluntarily sign the informed consent form, aged between 18 and 70 years (inclusive), regardless of gender;
- Single morning urine cadmium  $\leq 5 \mu\text{g/g}$  creatinine (with creatinine concentration  $\geq 0.3 \text{ g/L}$  and  $\leq 3 \text{ g/L}$ );
- eGFR  $\geq 30 \text{ mL/min/1.73 m}^2$  (calculated using the CKD-EPI formula).

### Exclusion (8)

- Participants who meet any of the following criteria will be excluded from this study:
- Currently suffering from any clinically significant disease that, in the investigator's judgment, poses a safety risk for participation in this clinical trial;
- Patients with a history of kidney disease requiring hemodialysis;
- Patients with a history of severe infusion-related allergic reactions, known allergies to three or more substances, or known hypersensitivity to any component of this product (e.g., disodium edetate, mannitol);
- Previous diagnosis of diabetes with poorly controlled blood glucose;
- ... and 3 more (see full listing online)

## Locations (1 total)

---

Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment, Guangzhou, Guangdong, China